Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Column

Clinical Pathways GPS
Ramifications of “Medicare for All” and Implications for Clinical Pathways
08/19/2019
Matthew Pakizegee, PharmD, MS
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and...
As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and...
As the...
08/19/2019
Journal of Clinical Pathways
Pharma Insights
The Evolution of Value Frameworks and What Is Next
08/19/2019
Jeremy Schafer, PharmD, MBA
Larry Blandford, PharmD—Column Editor
Value assessment in oncology is an emerging area of interest. Multiple value frameworks have been launched in the past 5 years to help stakeholders analyze the cost-effectiveness, or affordability, of oncology...
Value assessment in oncology is an emerging area of interest. Multiple value frameworks have been launched in the past 5 years to help stakeholders analyze the cost-effectiveness, or affordability, of oncology...
Value...
08/19/2019
Journal of Clinical Pathways

Advertisement

Counterpoint
Incorporating Patient Perspectives and Transparency for Patient-Centered Value Assessment
08/19/2019
Tom Valuck, MD, JD
Matthew Castner, MHA
Enhanced integration of the patient’s voice in health care is the next step in the evolution of a patient-centered delivery system. To remain in line with this evolution, value assessment should incorporate the...
Enhanced integration of the patient’s voice in health care is the next step in the evolution of a patient-centered delivery system. To remain in line with this evolution, value assessment should incorporate the...
...
08/19/2019
Journal of Clinical Pathways
Viewpoint
The Value of a Transparent, Inclusive Assessment Tool in Health Care
08/19/2019
Surabhi Dangi-Garimella, PhD
The value conversation for a drug, especially from a patient’s perspective, extends well beyond merely drug cost. In addition to utilization of cost-effectiveness analyses, decision makers need access to all relevant...
The value conversation for a drug, especially from a patient’s perspective, extends well beyond merely drug cost. In addition to utilization of cost-effectiveness analyses, decision makers need access to all relevant...
The...
08/19/2019
Journal of Clinical Pathways
Editor's Page
Predictive Methodologies to Better Manage Costs of Innovative Therapies
06/18/2019
Winston Wong, PharmD, Editor-in-Chief
Novel innovations in cell and gene therapies mark a new era in medicine whereby durable remission, and potentially cures, are within reach for several diseases. These advancements are clearly beneficial and have been...
Novel innovations in cell and gene therapies mark a new era in medicine whereby durable remission, and potentially cures, are within reach for several diseases. These advancements are clearly beneficial and have been...
Novel...
06/18/2019
Journal of Clinical Pathways

Advertisement

Editorial
The Real-Life Patient Impact of Pharmacy Benefit Managers
06/18/2019
Nicolas Ferreyros, Managing Director, Community Oncology Alliance
The Centers for Medicare & Medicaid Services (CMS) recently released a final rule for Medicare Part D that codified its decision to allow Medicare Advantage plans to use step therapy, or “fail first,” for new...
The Centers for Medicare & Medicaid Services (CMS) recently released a final rule for Medicare Part D that codified its decision to allow Medicare Advantage plans to use step therapy, or “fail first,” for new...
The...
06/18/2019
Journal of Clinical Pathways
Pharma Insights
Evolution of Hub Services
06/18/2019
Chris Dillon BS 
Chrysanthe Peteros, MPH
Larry Blandford, PharmD—Column Editor
What began as patient call centers for select complex medicines has expanded to a full suite of support services, ranging from financial assistance to patient education: so-called hub services have become ubiquitous...
What began as patient call centers for select complex medicines has expanded to a full suite of support services, ranging from financial assistance to patient education: so-called hub services have become ubiquitous...
What...
06/18/2019
Journal of Clinical Pathways
Business of Pathways
Cell and Gene Therapies: Paying It Forward and Adjusting Payment Systems for the Age of Cures
06/18/2019
Sean McElligott, MS
Ira Klein, MD, MBA, FACP—Column Editor
Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...
Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...
Cell...
06/18/2019
Journal of Clinical Pathways

Advertisement

Editor's Page
Managing a Successful Pathways Program
05/15/2019
Winston Wong, PharmD, Editor-in-Chief
Many oncology practices have adopted clinical pathways over the last 5 years with varying degrees of success. These mixed results may stem from a lack of understanding or full commitment from practices in terms of...
Many oncology practices have adopted clinical pathways over the last 5 years with varying degrees of success. These mixed results may stem from a lack of understanding or full commitment from practices in terms of...
Many...
05/15/2019
Journal of Clinical Pathways
Clinical Pathways GPS
CMS Policies Concerning CAR T-Cell Therapy
05/15/2019
Matthew Pakizegee, PharmD, MS
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Chimeric antigen receptor (CAR) T-cell therapy is a new form of cancer therapy that uses a patient’s own immune system to fight the disease. This type of cell therapy uses an individualized process to develop a...
Chimeric antigen receptor (CAR) T-cell therapy is a new form of cancer therapy that uses a patient’s own immune system to fight the disease. This type of cell therapy uses an individualized process to develop a...
...
05/15/2019
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use